Tweet
Redefining First-Line EGFR+ NSCLC with Subcutaneous Amivantamab & LazertinibByNicolas Girard, MD, PhDApril 2nd 2026
FDA Grants Breakthrough Therapy Designation to Plixorafenib for BRAF V600E GliomaBySabrina SeraniApril 2nd 2026
Navigating Genomic Assays and Clinical Evidence in Early Breast CancerByTargeted Oncology StaffApril 1st 2026